权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Analysis of mechanism that control B cell activation by using monoclonal antibodies.

使用单克隆抗体分析控制 B 细胞活化的机制。

基本信息

批准号：
61480133
负责人：
UEDE Toshimitsu
金额：
$ 3.33万
依托单位：
Sapporo Medical College
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (B)
财政年份：
1986
资助国家：
日本
起止时间：
1986 至 1987
项目状态：
已结题

项目摘要

We have produced a battery of monoclonal antidobies that detect different cell-surface antigen systems of human lymphoid cells. Firstly, two antigen systems (L 29 and L 30) expressed on two distinct human B cell subpopulations were identified by using BL1-4D6 and TB3-7D5 monoclonal antibodies. B cells that express L 29 were large activated B cells located in the germinal center of lymphoid follicles. In contrast, B cell that express L 30 were resting B cells located in the mantle zone of lymphid follicles. Those L 30 positive B cells also expressed IgM and IgD on their cell surgace. Upon stimulation of peripheral blood lymphocytes by mitogen, the expression of L 30 became weak whereas the expression of L 29 became strong which was accompanied by IL 2 receptor and T10 antigen expression. Therefore,L 30 defines festing b cells whereas L 29 defines activated B cells. We have also generated a monoclonal antibody (L 10) that detect interleukin 2 receptor.Secondly, those monoclonal antibodies were used for the differential diagnosis of malignant lymbhomas and leukemias. Hairly cell leukemias express L 29 and L 30 aw well as IL-2 receptor (L 10). MOst cases of diffuse small cleaved cell lymphoma expressed L 30 and L 10 whereas they did not express L 29 antigen. Large cell and immunoblastic lymphomas express L 29 antigen, but did not express L 30 antigen.Thirdly, we have henerated a monoclonal antibody that react with an unique antigenic determinatnt of leukocyte-common antigen (LCA). LCA was known to beexpressed by variety of cells such as T cells B cells, macrophages and granulocytes. However, monoclonal antibody, Y1 only reacted with Jurkat cells. It is possible that LCA underwent antigenic modification upon trasformation of cells. It should be noted that Y1 antigen was also expressed by some ATL cells. Therefore, common cell surface antigen may express a unique antigenic determinant and this unique antigen may serve as tumor specific marker.

我们已经生产了一系列单克隆抗体，可以检测人类淋巴细胞的不同细胞表面抗原系统。首先，使用 BL1-4D6 和 TB3-7D5 单克隆抗体鉴定了在两个不同的人 B 细胞亚群上表达的两个抗原系统（L 29 和 L 30）。表达 L 29 的 B 细胞是位于淋巴滤泡生发中心的大型活化 B 细胞。相反，表达 L 30 的 B 细胞是位于淋巴滤泡外套区的静息 B 细胞。那些 L 30 阳性 B 细胞还在其细胞表面表达 IgM 和 IgD。丝裂原刺激外周血淋巴细胞后，L 30 表达减弱，L 29 表达增强，并伴有IL 2 受体和T10 抗原表达。因此，L 30 定义了感染 b 细胞，而 L 29 定义了激活的 B 细胞。我们还制备了检测白细胞介素2受体的单克隆抗体（L 10）。其次，这些单克隆抗体用于恶性淋巴瘤和白血病的鉴别诊断。毛细胞白血病表达 L 29 和 L 30 aw 以及 IL-2 受体 (L 10)。大多数弥漫性小裂细胞淋巴瘤病例表达L 30 和L 10，但不表达L 29 抗原。大细胞和免疫母细胞淋巴瘤表达L 29 抗原，但不表达L 30 抗原。第三，我们产生了与白细胞共同抗原(LCA)的独特抗原决定因素反应的单克隆抗体。已知LCA由多种细胞表达，例如T细胞、B细胞、巨噬细胞和粒细胞。然而，单克隆抗体Y1仅与Jurkat细胞发生反应。 LCA 可能在细胞转化时经历了抗原修饰。值得注意的是，一些ATL细胞也表达Y1抗原。因此，常见的细胞表面抗原可能表达独特的抗原决定簇，并且这种独特的抗原可以作为肿瘤特异性标志物。